ILK and SHP2 expression identify a poor prognostic cohort of EGFR-mutant lung cancer

EBioMedicine. 2019 Jan:39:5-6. doi: 10.1016/j.ebiom.2018.12.008. Epub 2018 Dec 13.

Authors

Carminia Maria Della Corte¹, Carl Michael Gay², Lauren Averett Byers², Floriana Morgillo³

Affiliations

¹ Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. Electronic address: [email protected].
² Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
³ Medical Oncology, Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.

No abstract available

Publication types

Comment

MeSH terms

Carcinoma, Non-Small-Cell Lung*
Cohort Studies
ErbB Receptors
Humans
Lung Neoplasms*
Prognosis

Substances

EGFR protein, human
ErbB Receptors

Grants and funding

T32 CA009666/CA/NCI NIH HHS/United States